Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer.
https://blogs.sciencemag.org/pipeline/archives/2020/04/11/what-do-the-new-remdesivir-data-mean
SARSとMERSの結果から考えると有効な治療薬やワクチンが開発されるというシナリオには悲観的にならざるを得ない。